Identification of Genes Affecting the Toxicity of Anti-Cancer Drug Bortezomib by Genome-Wide Screening in S. pombe by Takeda, Kojiro et al.
Identification of Genes Affecting the Toxicity of
Anti-Cancer Drug Bortezomib by Genome-Wide
Screening in S. pombe
Kojiro Takeda*, Ayaka Mori, Mitsuhiro Yanagida
G0 Cell Unit, Okinawa Institute of Science and Technology (OIST), Okinawa, Japan
Abstract
Bortezomib/PS-341/Velcade, a proteasome inhibitor, is widely used to treat multiple myeloma. While several mechanisms of
the cytotoxicity of the drug were proposed, the actual mechanism remains elusive. We aimed to identify genes affecting the
cytotoxicity of Bortezomib in the fission yeast S.pombe as the drug inhibits this organism’s cell division cycle like
proteasome mutants. Among the 2815 genes screened (covering 56% of total ORFs), 19 genes, whose deletions induce
strong synthetic lethality with Bortezomib, were identified. The products of the 19 genes included four ubiquitin enzymes
and one nuclear proteasome factor, and 13 of them are conserved in humans. Our results will provide useful information for
understanding the actions of Bortezomib within cells.
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Introduction
The ubiquitin/proteasome pathway is a major proteolytic
machinery in cells and has pivotal roles in the cell division cycle,
apoptosis, etc [1]. Therefore, this pathway is considered to be a
strong potential target of clinical treatment for diseases such as
cancer, and chemicals that modulate the activity of the ubiquitin/
proteasome pathway have been intensively investigated [2,3].
Bortezomib/PS-341/Velcade is a peptide boronic acid that
inhibits the chymotrypsin-like activity of the beta 5 subunit of
the proteasome in vitro. Bortezomib has strong potential anti-
tumor effects in in vitro and animal studies and has been
developed as an anti-cancer drug to treat multiple myeloma and
other cancers [3,4]. Inhibiting the proteasome causes pleiotropic
effects. Therefore, several mechanisms for the cytotoxicity of
Bortezomib have been suggested, like inhibition of anti-apoptotic
proteins, stabilization of p53, disturbance of cell cycle progres-
sion, etc [5]. To increase knowledge of the mechanisms of the
anti-tumor and adverse effects of Bortezomib, it will be beneficial
to identify genes involving in the cytotoxicity of this drug. A
pioneer effort to identify such genes was reported by Lightcap
group in 2010 [6].
The fission yeast Schizosaccharomyces pombe is a simple unicellular
eukaryote and has been used as a model organism of basic cell
biology, owing to its genetic tractability and its similarity to higher
eukaryotes. A library of 2815 gene-deleted strains is available for
genome-wide studies of drug sensitivity [7,8,9].
Here, we attempted to identify evolutionally conserved genes
affecting the cytotoxicity of Bortezomib by taking advantage of the
gene-deletion library in S. pombe and established a method to
perform genome-wide synthetic lethal screening with Bortezomib.
Among the 2815 genes screened, deletion strains of 19 genes had
strong synthetic lethality with Bortezomib (such genes were
hereafter designated as synthetic lethal with Bortezomib; SLB).
Of the 19 SLB genes, 13 are conserved from yeast to human and
include factors involved in ubiquitin/proteasome dependent
proteolysis, chromatin silencing, nuclear/cytoplasmic transporta-
tion, amino acid and vitamin metabolism, vesicular trafficking,
RNA metabolism, etc.
Results
Mitotic arrest and failure in chromosome segregation
induced by Bortezomib
We found that Bortezomib (LC Laboratories) effectively
inhibited proliferation of S. pombe, while MG132, an authentic
proteasome inhibitor in mammalian cells did not inhibit
proliferation (Figure S1). We then examined the level of poly-
ubiquitinated proteins in the presence or the absence of
Bortezomib (Figure S1). Log-phase cultures were harvested at 0,
4, and 9 hours after addition of 1 mM Bortezomib and total
proteins were extracted for immunoblot analysis. In the presence
of Bortezomib, poly-ubiquitinated proteins accumulated in a time-
dependent manner. Therefore, we concluded that Bortezomib
effectively inhibits cellular proliferation and proteolytic activity of
the proteasome in S. pombe.
Temperature-sensitive mutants of proteasome components
(mts3-1 for Rpn12 of 19S regulatory particle and mts2-1 for Rpt2
of 19S regulatory particle) are arrested at M phase due to the
inhibition of degradation of mitotic regulators like Cdc13 (cyclin)
[10,11]. This finding led us to examine in detail how Bortezomib
affects the cell cycle. After adding Bortezomib to mid log-phase
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time (Figure 1A). Cell proliferation eventually ceased and viability
decreased to 21, 10, and 4.7% at 4, 6, and 9 hours after adding
Bortezomib. Without Bortezomib, the cells continued dividing and
sustained viability. To examine how the cell cycle was affected by
Bortezomib, chromatin DNA, microtubules, and spindle pole
bodies (SPB: homologous to centrosome) were visualized by green
or red fluorescent protein tagging to histone H2A (for chromatin),
alpha-tubulin (microtuble) and Sid4 protein (SPB, the yeast
equivalent centrosome, shown as a dot in Figure 1C) respectively.
The ratio of cells with over-condensed chromosomes and
metaphase spindles was highest (30%) at 1 hour after Bortezomib
addition and subsequently decreased (Figure 1B and 1C-a). As the
ratio of metaphase cells decreased, the ratio of cells with a
displaced nucleus increased (Figure 1C-b), in which sister
chromatids were not separated and the nucleus was displaced
from the center. As the ratio of ‘displaced nuclei’ was highest at
4 h and decreased subsequently, anucleated cells and cells with a
giant nucleus increased (Figure 1B and C-c). This was likely the
result of cytokinesis completion in cells with a displaced nucleus.
Thus, in the presence of Bortezomib, cells were briefly arrested at
metaphase, unable to separate sister-chromatids, and viability was
lost. These phenotypes induced by Bortezomib are virtually
identical to mitotic defects caused by mts2-1, the temperature-
sensitive mutation in Rpt2 subunit of 19S particle [10]. In the case
of mts3-1 mutation (Rpn12 of 19S), metaphase arrest phenotype is
severer; 75% of cells are briefly arrested at metaphase [11]. In
both cases, metaphase arrest is temporal and the nucleus is
displaced subsequently as shown in the case of Bortezomib
treatment. Given that the defect in the metaphase/anaphase
Figure 1. Bortezomib induces metaphase arrest. (A) Bortezomib (1 mM) inhibited cellular proliferation. Concentrations of cells and viabilities
are presented. BZ: Bortezomib (B) Bortezomib (1 mM) inhibited the normal progression of the M phase. The graph indicates the ratio of cells with
metaphase spindles and over-condensed chromosomes (blue, cells shown in Figure 1C-a), cells with a displaced nucleus (red, Figure 1C-b), cells
without a nucleus and with a giant nucleus (orange, Figure 1C-c), and cells with chromosome torn by the septum (green, Figure 1C-d, and e). (C)
Chromosomes, microtubules, and SPB were observed in the presence of Bortezomib. Cells showing mitotic abnormalities correspondent to Figure 2B
are shown in a–e (upper panel: +BZ). Images of normal progression of cell division are shown in lower panel (2BZ). Bar=10 mm( D) Poly-
ubiquitinated cyclin/Cdc13 accumulated in the presence of Bortezomib. See text for details.
doi:10.1371/journal.pone.0022021.g001
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substrates of the proteasome such as Cdc13 (cyclin) should
accumulate [12]. To examine this, cells that ectopically expressed
hexa-histidine (his6)-tagged ubiquitin were prepared and cultured
in the presence or absence of Bortezomib for 4 h at 26uC. The
proteins were then extracted from both cultures under denaturing
conditions with 6M guanidine-HCl and the resulting extracts were
applied to TALON beads (Clontech), which absorb the his6 tag, to
purify the ubiquitinated-proteins. TALON-purified proteins were
analyzed by immunoblot using an antibody against Cdc13
(Figure 1D). In the presence of Bortezomib, multi-ubiquitinated
Cdc13 was observed, as reported in temperature-sensitive mutants
of the proteasome [12]. These results demonstrated that a
chemical inhibitor for the proteasome can be used to replace the
ts proteasome mutants. This drug might be useful to analyze the
phenotypes of proteasome-defect at a low temperature, for
example, in meiosis or in the experiments in which heat-shock
responses should be avoided. Therefore, we adopted Bortezomib
for further genetic screening to identify the genes that affect the
proteasomal dysfunction phenotype.
Proteasome-related mutants are hypersensitive to
Bortezomib
Prior to the comprehensive screening, we examined how the
Bortezomib cytotoxicity is affected by mutations related to the
ubiquitin/proteasome system. Compared to the wild type were five
proteasome related mutants as follows: mts2-1, mts3-1, pts1-727
(mutated in the beta 5 subunit of the 20S complex [13]), ump1-620
(mutated inthe20Smaturation factorUmp1 [13]), and Dcut8 (gene-
deletion mutant of cut8
+ required for the proper nuclear localization
of the proteasome [14,15]). Each strain was incubated on a rich
YES agar plate to form a colony and then spotted onto agar plates
containing 0, 100, 250, or 500 mM Bortezomib, assisted by a robot
system (RoToR, Singer, UK). After 3 days incubation at 26uC, the
colony formation ability of each stain was evaluated (Figure 2A and
B). The wild type formed colonies on all the plates, whereas
proteasome-related mutants were defective in colony-formation on
Bortezomib plates (Dcut8 at 100 mM and others at 500 mM). The
clear hypersensitivity of Dcut8 to Bortezomib led us to adopt the
above-described method for further genome-wide screening of
synthetic lethal mutants with Bortezomib.
Figure 2. Synthetic lethal screening with Bortezomib. (A) Strategy for synthetic lethal screening (B) Mutants of components of the ubiquitin/
proteasome pathway are hypersensitive to Bortezomib. Eight colonies of each strain were replica-plated onto agar plates with various concentrations
of Bortezomib and were incubated for 3 days at 26uC. (C) Summary of synthetic lethal screening with Bortezomib. See text for details. (D) Validation
of isolated mutants that had growth defects in 100 mM Bortezomib by spotting 5-fold serial dilutions of vegetative growing cells.
doi:10.1371/journal.pone.0022021.g002
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Bortezomib
To identify the genes affecting the cytotoxicity of Bortezomib in
S. pombe, we screened 2815 gene-deletion mutants for synthetic
growth inhibition on YES agar plates with Bortezomib using
Robot-assisted replica plating. From the primary screening, 59, 62,
and 135 strains were isolated that had growth defects in media
with 100, 250, and 500 mM Bortezomib, respectively. There was
no clear-cut Bortezomib-resistant mutant that grew faster than the
wild-type strain on 500 mM Bortezomib medium. A summary of
the screening is shown in Figure 2C (examples of raw results of the
primary screening and the list of genes are shown in Figure S2 and
Table S1). The 59 strains that had growth defects with 100 mM
Bortezomib were retested by spotting 5-fold serial dilutions of log-
phase cultures of each strain (from 10 cells to 6250 cells) onto YES
plates with and without Bortezomib (Figure 2D). We performed
these retests in duplicate. As a result, 19 gene-deletion mutants
reproducibly showed growth defects on YES plates with 100 mM
Bortezomib. Seventeen and 12 strains showed growth defects with
250 and 500 mM Bortezomib, respectively. The rest of the mutants
did not show clear growth defects with Bortezomib in the spotting
test. None of mutants tested on lower doses (1 nM–10 mM) of
Bortezomib showed significant growth defects (Figure S3).
Therefore, we adopted a 100 mM concentration of Bortezomib
for hypersensitivity screening of S.pombe mutants in our present
study, although in the previous and similar study on human cells, a
4 to 7-nM concentration of Bortezomib was used for screening [6].
The 19 genes that showed clear growth defects on 100 mM
Bortezomib plates in the spotting test were categorized according
to function: five belonged to ubiquitin/proteasome pathway, four
to nuclear/chromatin proteins and nuclear transport, three to
vesicular traffic, three to amino acid and vitamins metabolism,
three to RNA metabolism, and protein kinase A (Table 1). Table 1
lists the systematic names, primary names (if applicable), budding
yeast Saccharomyces cerevisiae and human orthologs, and a short
description of each SLB gene. Among the 19 SLB genes, 13 genes
are reported to have potential orthologs in humans.
Discussion
In the present study, we demonstrated that Bortezomib, an
inhibitor of the proteasome widely used as an anti-cancer drug,
effectively inhibits the proliferation of S.pombe and induces mitotic
arrest as well as temperature-sensitive mutations of the proteaso-
mal subunits. Nineteen gene deletion mutants were identified by
the genome-wide screening to be synthetic lethal with Bortezomib.
Despite the strong effect of Bortezomib to arrest the cell cycle,
another proteasome inhibitor, MG132, had weaker inhibitory
effects on proliferation in the present study. MG132 is, however,
reported to inhibit protesome-dependent proteolysis in the cell
lysate of S.pombe, indicating that the proteasome of S.pombe is
sensitive to this inhibitor [16]. In S.cerevisiae, MG132 is used to
inhibit proteolysis in vivo under the gene deletion of PDR5, the
major drug efflux pump, which might effectively excrete MG132
from the cell [17]. S.pombe possesses two PDR5 orthologs, Pdr1
Table 1. List of SLB genes.
S.pombe S.cerevisiae H.sapiens Function
ubiquitin/proteasome pof3 DIA2 STIP1 F-box protein SCF ubiquitin ligase
cul3/pcu3 CUL3 Cullin-3 cullin-RING based BC3B ubiquitn ligase
mug30 HUL3 HECTD2 HECT type ubiquitin ligase
ubp16 UBP10 BAB14306.1 ubiquitin C-terminal hydrolase
cut8 STS1/DBF8 tethering factor for nuclear proteasome
chromatin/nucleus chp1 chromodomain protein,
heterochromatin
rik1 CLRK ubiquitin ligase complex, gene
silencing
SPBC1271.05c YOR052C zf-AN1 type zinc finger protein
kap123 KAP123/YBR4 importin-4 Importin beta family
vesicle transport sec28 SEC28/ANU1 coatmer epsilon vesicle transport
ryh1/hos1 YPT6 Rab-6B vesicle transport, GTPase, TORC2
regulator
ftp105 ECM30 DMC1 C17orf28/DMC1 ortholog, Golgi
localization
metabolism SPAC10F6.13c ASP5/AAT1 NP002070 pyridoxal phosphate-dependent
aminotransferase
snz1 SNZ1 Pyridoxine biosynthesis protein
vht1 VHT1 $ biotin uptake
RNA metabolism rex3 REX3 GOR Exonuclease, involved in processing of
snRNA and rRNA
SPAC8C9.10c RRP14 SURF6 ribosome biogenesis
exo2 KEM1/DST2 XP033181 Exonuclease II
signal transduction pka1/git6 TPK1/2/3 PKA cAMP-dependent protein kinase
catalytic subunit
$: Five potential orthologs (accession numbers; NP_115671, XP_166184, AA29863, NP_001458.1 and NP_061837) are reported in GeneDB S. pombe (Sanger Institute).
doi:10.1371/journal.pone.0022021.t001
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might be due to their differences in cell permeability or the efficacy
of excretion by drug efflux pumps. Bortezomib may serve as a
useful tool to study the ubiquitin/proteasome pathway in S.pombe.
We performed the synthetic-lethal screen to identify genes that
affect sensitivity for Bortezomib, using the 2815 gene-deletion
mutants of S. pombe. Nineteen deletion mutants were identified
with severe growth defects induced by 100 mM Bortezomib (listed
in Table 1 and Figure 3). Five of the responsible genes (designated
SLB) were ubiquitin/proteasome-related: pof3, cul3, mug30,
ubp16 and cut8. Their synthetic lethality with Bortezomib might
be explained through the drug’s inhibitory action against
proteasome. For example, ubiquitin ligases provide the substrates
for proteasome so that diminishing both might cause severe
synthetic effects. Others have not been reported to be related to
proteasome function. However, some of SLB genes could still be
explained through the proteasome functions. For three vesicular
trafficking SLB genes (sec28, ftp105, and ryh1), defects in secretory
pathway invoke ER (endoplasmic reticulum) stress that may
enhance requirement of the proteasome activity [18]. One of
vesicular trafficking SLB genes, ftp105, encodes Golgi localizing
protein that was reported to interact with deubiquitinase Usp5 and
be required for the Golgi localization of Usp5 [19]. The human
ortholog of Ftp105 is C17orf28/DMC1 (down-regulated in
multiple cancers), a potential tumor suppressor [20]. Therefore,
the synthetic lethality of ftp105 deletion with Bortezomib will be
studied further in future. Ryh1 was recently reported to regulate
TORC 2 (target of rapamycin complex 2) in S.pombe [21].
Concerning nuclear SLB proteins, more proteasome might be
required when the chromatin dynamics is compromised in
deletion mutants of chromatin regulators, as the nuclear protea-
some is known to contribute to chromatin regulations like DNA
damage repair, DNA replication, and transcription [15,22,23,24].
One of nuclear SLB gene products is Rik1, a component of CLRK
ubiquitin ligase complex required for chromatin silencing [25,26].
Although substrates of CLRK ubiquitin ligase are not known, it
may be a curious experiment to examine whether Bortezomib
affects DNA chromatin silencing. PKA was reported to be
involved in metaphase/anaphase regulations in the fission yeast
and in Xenopus-egg systems in vitro [12,27,28]. While some of the
other SLB genes, such as vitamin metabolic factors, are difficult to
be explained, they might be implicated to one of very diverse
cellular functions of the proteasome. Bortezomib may possibly
have targets other than the proteasome within cells of S. pombe.
Thus evaluation of SLB genes apparently unrelated to ubiquitin/
proteasome might be worth for considering other targets.
Combination of SLB gene deletion and proteasomal tempera-
ture-sensitive mutations will be useful to judge whether the
synthetic lethality is due to inhibition of the proteasome or to other
perturbations caused by Bortezomib. If the synthetic lethality is
due to inhibition of the proteasome, the double mutant of the SLB
gene and the proteasome is expected to show a much severer
phenotype than a single proteasomal mutant. Actually, a mutant
of cut8, an SLB gene, shows synthetic lethality to proteasomal
mutations mts2-1 and mts3-1 [14]. Although it should be kept in
mind that Bortezomib has another target, the present results have
potentially important implications for basic proteasome biology by
opening avenues for discovering novel and unexpected relation-
ships between the proteasome and other cellular pathways. A
similar genome-wide screen in human cells suggested that protein
translations, ER/Golgi pathway, DNA damage repair pathway,
and regulation of Myc and polyamines are involved in
Bortezomib-induced cell death [6]. The findings of the present
study newly suggest that genes involved in vitamin and amino acid
metabolic pathways, chromatin silencing, nuclear/cytoplasm
shuttling, and the cAMP pathway are related to the proteasome
Figure 3. Summary of identified SLB genes. Thirteen conserved SLB genes are shown in red.
doi:10.1371/journal.pone.0022021.g003
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to understand the mechanisms of the synthetic lethality of these
unexpected SLB gene deletions with Bortezomib.
We identified 13 conserved SLB genes potentially interesting
for further studies. As mentioned in the Results, 4 to 7 nM of
Bortezomib was used to screen genes affecting the cytotoxicity of
Bortezomib in cancer cell lines, and 100 mMo fB o r t e z o m i bw a s
used for S.pombe mutant screening in the present study. The
difference in Bortezomib sensitivity might reflect the difference in
the biology of these organisms, such as drug permeability and
drug excretion. In general, yeast cells are more resistant to
perturbations by chemical inhibitors. Therefore, human ortho-
logs of conserved SLB genes should be examined by small
interference-RNA to see whether their knockdown affects the
survivability of human cells at lower doses of Bortezomib. If the
same synthetic effects occur in human cells, such SLB genes have
potential for the innovation of new therapies or diagnoses. For
example, if chemical inhibitors for these conserved SLB products
are developed, such chemicals will be candidates used for cocktail
therapy with Bortezomib. On the other hand, patients with a
genetically weak background due to these SLB orthologs might
have severe adverse effects upon Bortezomib administration.
Thus further investigations on the SLB orthologs in human are
expected in future.
Materials and Methods
Strain, medium, culture, and drug treatments
S. pombe heterothallic haploids 972h
2 and 975h
+ and their
derivatives were used. Complete rich YE, YES and minimal
EMM2 media were used [29]. Stock solutions of Bortezomib (LC
Laboratories, Woburn, MA) were prepared in DMSO and drugs
were added to liquid culture or agar medium at the indicated
concentration.
Synthetic lethal screening
For genome-wide screening, we adopted the deletion library of
the S. pombe haploid purchased from Bioneer Corp. (Korea). The
control wild type strains are ED666 (h
+ ade6-M210 ura4-D18 leu1-
32) and ED668 (h
+ ade6-M216 ura4-D18 leu1-32), which were also
purchased from Bioneer Corp. The haploid gene-deletion library
was provided as glycerol stocks in 96-well plates. First, 5 ml of each
stock of deletion strain was spotted onto YES plates from a 96-well
plate using the laboratory automation system BioMek FX
(Beckman Coulter, Brea, CA). After 3 days incubation at 26uC,
a colony of each strain was picked-up and spotted onto another
YES plate (considered the mother plates) using the RoToR robot
(Singer Instruments, UK). One colony was quadruplicated to
check reproducibility. From the mother plates, spotted colonies
were again picked-up and spotted onto YES plates containing 0,
100, 250, and 500 mM Bortezomib, respectively. Spotted plates
with various concentrations of the drug were incubated for 3 days
at 26uC and the colony formation of each strain was evaluated.
For validation of the primary screening, Bortezomib sensitivities of
selected strains from the primary screening were retested using
spotting tests.
Immunoblot and protein purification
For immunoblot analysis, total proteins were extracted using the
trichloroacetic acid (TCA) method. Identical amounts of proteins
were separated by SDS-PAGE gel and blotted to nitrocellulose
membranes. Anti-poly-Ubiquitin (FK-2; mouse monoclonal,
MBL, Japan), anti-alpha-tubulin (TAT1; mouse monoclonal, a
gift from Dr. Gull) and anti-Cdc13 (rabbit polyclonal) were used as
primary antibodies. Horseradish peroxidase-conjugated secondary
antibodies and an ECL chemiluminescence system (GE Health-
care) were used to amplify signal expression. To purify
ubiquitinated proteins, the previously described method was
applied with minor modification [15].
Fluorescent microscopy
All images were acquired using a fluorescent microscope setting
AxioPlan 2 (Zeiss, Germany). Methods of construction of GFP or
RFP fused gene were previously described [30].
Supporting Information
Figure S1 Bortezomib inhibits proliferation of S.pombe.
(A) Bortezomib and MG-132 were added to a log-phase culture of
S. pombe at the indicated concentrations and cellular proliferation
was examined for 8 hours. Fold-increases at 8 hours after drug
addition are presented on the Y-axis. (B) Levels of poly-
ubiquitinated proteins were examined in the presence (+)o r
absence (2) of 1 mM Bortezomib. Poly-ubiquitinated proteins
accumulated in a time-dependent manner after the addition of
Bortezomib.
(TIF)
Figure S2 An example of the primary screening is
shown. As described in the text, every colony of each gene-
deletion strain was spotted to each position (A1, A2…) of YES
agar plates with 0, 100, 250, and 500 mM Bortezomib. To screen
2815 strains, 31 sets of these plates were prepared. After
incubating at 26uC for 3 days, colony formation was evaluated.
Wild-type strains were spotted to positions H2 and H3 (white
broken line). Strains spotted onto A3, B8, B10, and C10 were
selected as candidates showing severe growth defects with 100 mM
Bortezomib and were retested by serial dilution spotting.
(TIF)
Figure S3 Sensitivity to lower doses of Bortezomib.
Colony-formation ability of five slb mutants was examined on YES
agar medium containing 0, 1 nM, 10 nM, 100 nM, 1 mM,
10 mM, and 100 mM Bortezomib as described in Figure 2 (D).
Under 10 mM Bortezomib, significant growth defect was not
observed.
(TIF)
Table S1 List of genes that were identified to show
growth defect in the presence of 100, 250 and 500 mM
Bortezomib from the primary screening.
(XLS)
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